Tracking Who Makes Money On A Brand-Name Drug
KHN’s Julie Appleby joined forces with USA Today to create this chart, which details the various industry players and how they contribute to a prescription drug’s cost.
Drug Costs
641 - 660 of 698 Results
-
-
Young Boy’s Struggle To Survive Sparked Push For Drugs For Terminally Ill
Ten-year-old Josh Hardy died last month. His struggle to survive helped to spur laws to get unapproved drugs to the terminally ill.
By Liz Szabo -
The Orphan Drug Machine
A Golden Ticket That Fast-Tracks A Drug Through The FDA
A voucher awarded to companies that find treatments for rare childhood diseases can be sold to the highest bidder — and then used to speed up approvals for much more common drugs.
-
Specialty Drug Costs Soar 30% For California Pension Fund
Such medications account for more than a quarter of the state agency’s $2.1 billion in pharmacy costs.
By Chad Terhune -
It’s Not Just For Kids: Medicare EpiPen Spending Up 1,100 Percent
The number of prescriptions for Medicare beneficiaries is on the rise, too.
By Julie Appleby and Mary Agnes Carey -
Veterans Courted In California’s Ballot Fight Over Curbing Drug Prices
The initiative would prohibit California state agencies from paying more for a prescription drug than what the Department of Veterans Affairs pays. Both sides are deploying veterans’ sympathetic and trusted image to win over voters.
-
FDA Approves First Drug To Treat Rare Form Of Muscular Dystrophy
The FDA, reacting to lobbying by patients and families, has approved a drug for Duchenne muscular dystrophy, a rare and lethal disease.
By Liz Szabo -
Candidates Decry High Drug Prices, But They Have Few Options For Voters
Drug prices rise for a variety of reasons but opportunities for the government to control them is limited.
By Julie Rovner -
Study: Health Spending Related To Opioid Treatment Rose More Than 1,300 Percent
Based on an analysis of insurance company payments, emergency room visits and lab tests were responsible for much of the overall spending.
-
Consumer Group Questions Role of Drug Costs In California Premium Hikes
Consumers Union says Anthem Inc. and Blue Shield of California may be exploiting furor over prescription drug prices. State regulators are looking into the issue.
By Chad Terhune -
Study Says Concerns About Orphan Drug Spending Are Unjustified
A study in Health Affairs concludes that orphan drugs for rare diseases are not having a widespread or deep impact on health care spending.
-
EpiPen Controversy Fuels Concerns Over Generic Drug Approval Backlog
Four years after a huge push to speed generics to market, the FDA has more than 4,000 generics waiting for approval.
-
Government-Protected ‘Monopolies’ Drive Drug Prices Higher, Study Says
Researchers at Harvard University examined thousands of studies to determine why drug prices have climbed and what might be done about it.
-
California Lawmaker Pulls Plug On Drug Price Transparency Bill
The legislation would have required drug companies to notify the state and insurers about expensive new treatments or price hikes.
-
Fraud Concerns Emerge As Compounding Drug Sales Skyrocket
Federal spending has soared for drugs that are handmade in local pharmacies, and federal investigators are raising concerns about fraud or overbilling.
-
Sounds Like A Good Idea? Regulating Drug Prices
Presidential candidates from both parties have proposals they say would help lower the cost of prescription drugs. But most experts say that efforts to regulate prices might not end up saving much money.
By Julie Rovner and Francis Ying -
Medical Marijuana Linked To Modest Budget Benefits For Medicare Part D, Study Finds
A Health Affairs study determines that Part D spending went down slightly on prescription drugs for which medical marijuana is viewed as a possible alternative.
-
Study: Brand-Name Drugs’ High Copays Soak Medicare Part D Patients
A study in Health Affairs finds Medicare Part D beneficiaries were charged copays averaging 10.5 times more for Crestor and Nexium than generic drugs would have cost them.
By Rachel Bluth -
Medicaid, Private Insurers Begin To Lift Curbs On Pricey Hepatitis C Drugs
Over the past few months, Massachusetts, Florida, New York, Delaware and Washington have lifted restrictions on the expensive medications, and private insurers around the country are also making the changes.
-
Anthem, Express Scripts Face Legal Challenge Over Prescription Drug Prices
The case alleges that insured consumers were overcharged because of a contract agreement.